Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.

New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...

"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...

Empagliflozin, an SGLT2 inhibitor, is proven safe and effective for heart attack patients, offering a new treatment option to ...

Recurrent stroke risk was lower among patients with type 2 diabetes who used SGLT2 inhibitors within 3 months of ischemic stroke.

Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...

Citation: SGLT2 inhibitor empagliflozin is shown to be safe and effective for treating patients who have suffered a heart attack (2024, September 2) retrieved 16 September 2024 from https ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. New research ...

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to ...